RUBICON ORGANICS INC

Rubicon Organics reports an 11% revenue increase in Q1 2026 to 13.7 million CAD, but records a gross margin of 20% (previous year 31%) and an adjusted EBITDA loss of 580,000 CAD versus +700,000 CAD in Q1 2025. The share price fell 1.01% after the results. Management expects margin improvement in the second half of the year from contributions of the Cascadia facility and forecasts EPS of $0.01 for Q2 and $0.02 for Q3 and Q4; revenue guidance is $52.64 million for 2026 and $61.18 million for 2027. » More on de.investing.com

Rubicon Organics reported Q4 2025 EPS of CAD 0.01 (expectation CAD 0.005) and revenue of CAD 16.5m (up 16% year‑on‑year). Adjusted EBITDA rose to CAD 5.0m (up 25%) and gross margin was 32%. Despite the positive results, the stock fell 6.12% to CAD 0.46, partly due to mixed market sentiment and proximity to its 52‑week low; an eight‑week strike at the distributor in B.C. had dampened revenue growth. For 2026, management expects improved margins, efficiency gains, expansion in the premium‑vape segment and international growth. » More on de.investing.com

Rubicon Organics reported earnings per share of CAD 0.04 for Q3 2025 versus an expected CAD 0.00, while revenue of CAD 15.6 million narrowly missed the CAD 15.7 million forecast. Net revenue rose 16% year over year and gross profit increased 32%; adjusted EBITDA was positive for the sixth consecutive quarter. The stock rose 1.96% after the results. The company plans to ramp up the Cascadia facility by mid‑2026 and targets mid‑40s percent gross margins, but sees near‑term risks from high ramp costs and hurdles to international expansion. » More on de.investing.com